Application | Comment | Organism |
---|---|---|
drug development | glutaminyl cyclase is a drug target to diminish pE-Abeta formation | Mus musculus |
pharmacology | glutaminyl cyclase is a drug target to diminish pE-Abeta formation | Mus musculus |
Protein Variants | Comment | Organism |
---|---|---|
additional information | generation of QC knock-out mice with no neuronal labeling of the enzyme. Deposition of pE-Abeta only in the brain regions of amyloid precursor protein (APP)-transgenic Tg2576 mice with detectable human APP and endogenous QC expression, such as the hippocampus, piriform cortex, and amygdala. Identification of brain regions with substantial expression of human APP and QC in the absence of pE-Abeta deposition (the Edinger-Westphal nucleus and locus coeruleus). In these brain regions, the enzymes required to generate N-truncated Abeta peptides as substrates for QC might be lacking. In APP-transgenic Tg2576 mice, pE-Abeta deposits concentrate in the neocortex and hippocampus and are not detected in the respective subcortical structures affected by this pathology in Alzheimer's disease brains | Mus musculus |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
L-glutaminyl-Abeta(3-42) peptide | Mus musculus | a glutamate residue (E) is exposed at position 3 of Abeta(3-42) and can be converted by the enzymatic activity of glutaminyl cyclase (QC) to pE resulting in the peptide pE-Abeta(3-42). 5-Oxoproline ring formation under liberation of water. Slow conversion of N-terminal glutamate under slightly acidic pH conditions, as compared with the much faster pE formation from N-terminal glutamine | 5-oxoprolyl-Abeta(3-42) peptide + NH3 | - |
? | |
L-glutaminyl-peptide | Mus musculus | - |
5-oxoprolyl-peptide + NH3 | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | Q9CYK2 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
amygdala | - |
Mus musculus | - |
brain | - |
Mus musculus | - |
Edinger-Westphal nucleus | - |
Mus musculus | - |
hippocampus | in interneurons and pyramidal cells, not in granule cells | Mus musculus | - |
lateral hypothalamus | - |
Mus musculus | - |
locus ceruleus | - |
Mus musculus | - |
additional information | not in anterodorsal thalamic nucleus, perifornical nucleus, and granule cells | Mus musculus | - |
piriform area | - |
Mus musculus | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
L-glutaminyl-Abeta(3-42) peptide | - |
Mus musculus | 5-oxoprolyl-Abeta(3-42) peptide + NH3 | - |
? | |
L-glutaminyl-Abeta(3-42) peptide | a glutamate residue (E) is exposed at position 3 of Abeta(3-42) and can be converted by the enzymatic activity of glutaminyl cyclase (QC) to pE resulting in the peptide pE-Abeta(3-42). 5-Oxoproline ring formation under liberation of water. Slow conversion of N-terminal glutamate under slightly acidic pH conditions, as compared with the much faster pE formation from N-terminal glutamine | Mus musculus | 5-oxoprolyl-Abeta(3-42) peptide + NH3 | - |
? | |
L-glutaminyl-peptide | - |
Mus musculus | 5-oxoprolyl-peptide + NH3 | - |
? |
Synonyms | Comment | Organism |
---|---|---|
glutaminyl cyclase | - |
Mus musculus |
General Information | Comment | Organism |
---|---|---|
metabolism | evidence for an involvement of glutaminyl cyclase (QC) in Alzheimer's disease pathogenesis via QC-catalyzed pE-Abeta formation | Mus musculus |
physiological function | the enzyme glutaminyl cyclase (QC) acts as glutamyl cyclase to catalyze pE-Abeta formation from N-terminal glutamate. A glutamate residue (E) is exposed at position 3 of Abeta(3-42) and can be converted by the enzymatic activity of glutaminyl cyclase (QC) to pE resulting in the peptide pE-Abeta(3-42). Slow conversion of N-terminal glutamate under slightly acidic pH conditions, as compared with the much faster pE formation from N-terminal glutamine | Mus musculus |